BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients
BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients
Not yet recruiting · NCT07071844 · Registry updated 2025-07-17Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients | Cytopenia, Digestive System Diseases, Digestive System Neoplasms, Hemic and Lymphatic Diseases, Neoplasms by Site, agranulocytosis, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, hematologic disorder, intestinal disorder, leukocyte disorder, leukopenia, neoplasm, neutropenia, rectal disorder | Not yet recruiting | Phase 2 | 2025-07-17 | NCT07071844 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| GERCOR - Multidisciplinary Oncology Cooperative Group | 25 |
| Servier | 21 |
10 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Centre François Baclesse | Caen | France | 39 |
| Centre Hospitaler Universitaire de Lille | Lille | France | 1 |
| Centre Hospitalier Departemental Vendee - Site Des Oudairies | La Roche-sur-Yon | France | 1 |
| Centre Hospitalier Universitaire -Besançon | Besançon | France | 1 |
| CHU Amiens | Amiens | France | 49 |
| CHU de BORDEAUX Hôpital HAUT-LEVEQUE | Pessac | France | 1 |
| CHU Saint-Antoine | Paris | France | 2 |
| Hôpital privé Jean Mermoz | Lyon | France | 18 |
| Institut de cancérologie Strasbourg Europe | Strasbourg | France | 5 |
| Institut Saint Catherine | Paris | France | 1 |